In conclusion, our data demonstrate that PI3Kγ and PI3Kδ play important roles in processes critical for MCL pathophysiology and therefore suggest that duvelisib would provide an effective treatment for MCL patients, including those patients with TP53 aberrations, a patient group for whom there are few treatment options. Here, TP53 is linked to mantle cell lymphoma.